Editas Medicine, Inc. (EDIT)
EDIT Stock Price Chart
Explore Editas Medicine, Inc. interactive price chart. Choose custom timeframes to analyze EDIT price movements and trends.
EDIT Company Profile
Discover essential business fundamentals and corporate details for Editas Medicine, Inc. (EDIT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Feb 2016
Employees
87.00
Website
https://www.editasmedicine.comCEO
Gilmore O'Neill
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
EDIT Financial Timeline
Browse a chronological timeline of Editas Medicine, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.30, while revenue estimate is $2.85m.
Earnings released on 5 May 2026
EPS came in at -$0.26 surpassing the estimated -$0.30 by +13.33%, while revenue for the quarter reached $2.83m , missing expectations by -55.58%.
Earnings released on 9 Mar 2026
EPS came in at -$0.06 surpassing the estimated -$0.27 by +77.78%, while revenue for the quarter reached $24.74m , beating expectations by +196.33%.
Earnings released on 10 Nov 2025
EPS came in at -$0.28 surpassing the estimated -$0.38 by +26.32%, while revenue for the quarter reached $7.54m , missing expectations by -10.77%.
Earnings released on 12 Aug 2025
EPS came in at -$0.63 falling short of the estimated -$0.41 by -53.66%, while revenue for the quarter reached $3.58m , beating expectations by +97.05%.
Earnings released on 12 May 2025
EPS came in at -$0.43 surpassing the estimated -$0.51 by +15.69%, while revenue for the quarter reached $4.66m , beating expectations by +559.68%.
Earnings released on 5 Mar 2025
EPS came in at -$0.55 falling short of the estimated -$0.39 by -41.03%, while revenue for the quarter reached $30.60m , beating expectations by +4.68k%.
Earnings released on 4 Nov 2024
EPS came in at -$0.75 surpassing the estimated -$0.76 by +1.32%, while revenue for the quarter reached $61.00k , missing expectations by -99.79%.
Earnings released on 7 Aug 2024
EPS came in at -$0.82 falling short of the estimated -$0.69 by -18.84%, while revenue for the quarter reached $513.00k , missing expectations by -89.90%.
Earnings released on 8 May 2024
EPS came in at -$0.76 falling short of the estimated -$0.63 by -20.63%, while revenue for the quarter reached $1.14m , missing expectations by -85.63%.
Earnings released on 28 Feb 2024
EPS came in at -$0.23 surpassing the estimated -$0.52 by +55.77%, while revenue for the quarter reached $60.05m , beating expectations by +656.28%.
Earnings released on 3 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.64 by +14.06%, while revenue for the quarter reached $5.34m , beating expectations by +56.02%.
Earnings released on 2 Aug 2023
EPS came in at -$0.56 surpassing the estimated -$0.76 by +26.32%, while revenue for the quarter reached $2.89m , missing expectations by -30.77%.
Earnings released on 5 May 2023
EPS came in at -$0.71 surpassing the estimated -$0.79 by +10.13%, while revenue for the quarter reached $9.85m , beating expectations by +227.28%.
Earnings released on 22 Feb 2023
EPS came in at -$0.88 falling short of the estimated -$0.84 by -4.76%, while revenue for the quarter reached $6.54m , beating expectations by +78.68%.
Earnings released on 2 Nov 2022
EPS came in at -$0.81 surpassing the estimated -$0.87 by +6.90%, while revenue for the quarter reached $42.00k , missing expectations by -99.04%.
Earnings released on 3 Aug 2022
EPS came in at -$0.78 surpassing the estimated -$0.84 by +7.14%, while revenue for the quarter reached $6.36m , beating expectations by +48.28%.
Earnings released on 4 May 2022
EPS came in at -$0.74 surpassing the estimated -$0.81 by +8.64%, while revenue for the quarter reached $6.77m , beating expectations by +75.76%.
Earnings released on 24 Feb 2022
EPS came in at -$0.61 surpassing the estimated -$0.78 by +21.79%, while revenue for the quarter reached $12.47m , beating expectations by +168.51%.
Earnings released on 8 Nov 2021
EPS came in at -$0.57 surpassing the estimated -$0.86 by +33.72%, while revenue for the quarter reached $6.20m , beating expectations by +9.29%.
Earnings released on 4 Aug 2021
EPS came in at -$0.81 surpassing the estimated -$0.85 by +4.71%, while revenue for the quarter reached $379.00k , meeting expectations.
EDIT Stock Performance
Access detailed EDIT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
